Core Insights - The company is committed to the inheritance and innovation of traditional Chinese medicine, focusing on pharmaceutical manufacturing, distribution, and health sectors [1] - The company is accelerating the resumption of production for quality products like Pearl Eye Drops, guided by clinical value and efficacy [1] - The company has made significant progress in drug re-registration, with 53 drugs obtaining re-registration approval since the beginning of 2025, surpassing the total for the entire year of 2024 [1] - The company is leveraging existing product advantages to launch a series of products, including Iron Skin Feng Dou Tablets and Goji Berry Extract, to meet diverse consumer needs [1] - The company is planning capacity expansion based on market demand and strategic factors, with stable production operations [1] - A subsidiary is expected to invest 100 million yuan in capacity enhancement and technological transformation, significantly increasing the extraction capacity of traditional Chinese medicine [1] - The first phase of the project has been capped as of May 29, 2023, with production expected to commence by the end of 2026 [1]